Skip to main content

In Brief This Week: VolitionRx, Bio-Techne, Biocept, Meridian Bioscience, and More

NEW YORK (360Dx) – VolitionRx reported a second quarter net loss of $3.5 million, or $.13 per share, compared to a net loss of $2.9 million, or $.13 per share, a year ago. The company said it had $16.5 million in cash and cash equivalents on June 30. During the quarter, it initiated regulatory approval for its tests in Taiwan and Singapore, and noted that if it gets approval in Singapore, it would provide VolitionRx access to nine other South Asian markets. The company also established a wholly owned US subsidiary, Volition America, based in Austin, Texas.


Bio-Techne this week reported that its net sales for its fiscal fourth quarter rose 16 percent year over year to $156.6 million. For the quarter ended June 30, its diagnostics segment net sales rose 14 percent year over year to $32.6 million.


Biocept said it has entered into a preferred provider agreement with Scripps Health Plan in San Diego to make the firm's Target Selector liquid biopsy tests available to cancer patients within the health plan. The firm noted that more than 190 million covered lives have in-network access to its liquid biopsy platform because of this and other health plan agreements.

Biocept's President and CEO Michael Nall said in a statement that its tests "can be used to improve treatment outcomes by helping physicians rapidly obtain the actionable information they need to design personalized treatment plans for their cancer patients."


Meridian Bioscience said it has initiated clinical trials for its illumigene molecular amplification test designed to detect congenital cytomegalovirus infection in newborns from saliva. According to the US Centers for Disease Control and Prevention, 1 out of every 200 babies are born with congenital CMV infection.


Isohelix said that it has registered its range of GeneFiX DNA Saliva Collectors with the China Food and Drug Administration as certified IVD medical devices. The registration is filed alongside other worldwide registrations, such as the CE-IVD certification, Isohelix CEO Tom Hole said in a statement.

Isohelix manufactures a broad range of DNA and RNA saliva and buccal cell collection devices for medical, diagnostic, and research use, as well as kits for manual and automated stabilization and extraction of DNA and RNA.


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on the 360Dx site.